Page 159 - CW E-Magazine (9-1-2024)

News from Abroad

the Carbopath Circular Carbon Meth-
anol (CCM) concept and the plant will
soon begin production of bio-methanol
using unused biogas generated from a
nearby sewage treatment plant (septic
centre) owned by Niigata Prefecture as
a feedstock. MGC is also studying the
recycling of waste plastics into metha-
nol through gasification and the pro-
duction of methanol from CO emis-
2
sions with various companies in Japan.
MGC announced the receipt of Inter- tions including as a chemical feedstock,
In Australia, the company is consi- national Sustainability and Carbon Certi- fuel, and hydrogen carrier, all under the
dering the feasibility of commercialising fication (ISCC) PLUS for bio-methanol Carbopath brand. This certification also
renewable methanol from CO and and dimethyl ether (DME) produced at facilitates the use of bio-methanol in
2
renewable hydrogen in collaboration its Niigata plant. the production of methanol derivative
with Cement Australia. Together with products.
conventional methanol, Carbopath will With this certification, MGC can
contribute to the decarbonization of manufacture and sell bio-methanol DME is produced by dehydrating
shipping around the world. produced from the unused biogas as an methanol and has various uses includ-
ISCC PLUS certified product manu- ing as an injection agent and foaming
ISCC PLUS for bio-methanol and factured via the mass balance method. agent. When DME is used as a fuel, its
DME Bio-methanol produced via this method physical properties are similar to those
In another unrelated development, will be used in a wide range of applica- of LPG.
Asahi Kasei opens new bioprocess technical centre

in China

Japan’s Asahi Kasei Medical Co.
Ltd. has announced that its Chinese
subsidiaries – Asahi Kasei Biopro-
cess (Shanghai) Co. Ltd. (AKBC) and
Asahi Kasei Microza (Hangzhou) Co.
Ltd. (AKMH) – have opened the Asahi
Kasei (China) Bioprocess Technical
Centre (CBTC) in Suzhou City, Jiangsu
Province.

The Bioprocess Division, which
focuses on biosafety testing, biopharma-
ceutical CDMO business develop-
ment, and the manufacture and sale of
bioprocess-related equipment used in
the production of biotherapeutics, is a
rapidly growing division at Asahi Kasei
Medical. of Planova virus removal filters, Bio- customers, AKBC opened the CBTC
Optimal microfilters, and related in collaboration with AKMH, which
AKBC was established in 2020 to equipment. In order to expand services handles the import and sale of Microza
provide services to the Chinese mar- through technical advice and support industrial filtration membranes and
ket and manage the import and sale as well as hands-on training for local systems.

Chemical Weekly January 9, 2024 159

Contents Index to Advertisers Index to Products Advertised